Omegaven Emulsion

PreclinicalSmall molecule

FFresenius

Omegaven Emulsion is one of 5 small molecule programs targeting Cholestasis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

CholestasisActive, not recruiting

CholestasisPreclinical

Active, not recruiting

Competition

Competitive Landscape

4 competitors in Cholestasis

#DrugCompanyPhaseTrials

Lynavoy

IIntercept Pharmaceuticals

Phase 3

1 2

IC-Green

PProvepharm SAS

Phase 1

1 3

Tauroursodeoxycholic Acid

HHumanitas Mirasole SpA

Preclinical

1 4

Kinevac

UUniversity of Maia

Preclinical

1 5

Omegaven Emulsion

FFresenius

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Recruiting

Parenteral Nutrition

NCT06274788

Clinical

Trials by Indication[1]

Cholestasis1 trial

Safety of Omegaven in Pediatric Patients With Parenteral Nutrition-Associated Cholestasis (PNAC)

Withdrawn·FFresenius··NCT04807478

Parenteral Nutrition1 trial

Title: A Single-arm, Open-label, Prospective, Multicenter Safety Study to Evaluate the Occurrence of Essential Fatty Acid Deficiency (EFAD) in Pediatric Patients With Parenteral Nutrition-associated Cholestasis (PNAC) Who Require More Than Eight Weeks of Omegaven Treatment

Recruiting·FFresenius··NCT06274788·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Omegaven Emulsion. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Omegaven Emulsion compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Omegaven Emulsion. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Fresenius company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: FFresenius

Omegaven Emulsion

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Cholestasis1 trial

Parenteral Nutrition1 trial

References

Drug Info

Quick Facts

Related News